Who are Influenza's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Plegisol In Plastic Container, Plegisol In Plastic Container, Treatment C, Licensed Influenza Vaccine 2, Pf-07941944, Zithromax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/influenza-and-covid-19-combination-b.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Influenza — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Influenza (Influenza and COVID-19 Combination B) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-Standardized Plant Allergenic Extract [EPC]. Area: Infectious Disease.

marketed Non-Standardized Plant Allergenic Extract [EPC] Not specified Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Influenza (Influenza and COVID-19 Combination B) — BioNTech.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Influenza TARGET	Influenza and COVID-19 Combination B	BioNTech	marketed	Non-Standardized Plant Allergenic Extract [EPC]	Not specified
Plegisol In Plastic Container	Sodium Chloride	Baxter	marketed	Electrolyte solution	Not specified	1965-01-01
Plegisol In Plastic Container	Sodium Chloride	Baxter	marketed	Electrolyte solution	Not specified	1965-01-01
Treatment C	treatment-c	Pfizer	marketed	Not specified	Not specified
Licensed Influenza Vaccine 2	Licensed Influenza Vaccine 2	BioNTech	marketed	Vaccine	Not specified
Pf-07941944	pf-07941944	Pfizer	marketed	Small molecule	Not specified
Zithromax	Azithromycin	Pfizer Inc.	marketed	Macrolide	Not specified in label

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-Standardized Plant Allergenic Extract [EPC] class)

· 4 drugs in this class
BioNTech · 2 drugs in this class
Dey · 1 drug in this class
Fudan University · 1 drug in this class
Green Cross Corporation · 1 drug in this class
Mdd Us · 1 drug in this class
Merck · 1 drug in this class
National Cancer Institute (NCI) · 1 drug in this class
National Center for Complementary and Integrative Health (NCCIH) · 1 drug in this class
Novartis Pharmaceuticals · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Influenza — Competitive Intelligence Brief. https://druglandscape.com/ci/influenza-and-covid-19-combination-b. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab